2025
Acceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study
Chayama K, Ng C, Brohman I, Mansoor M, Small W, Philbin M, Collins A, McNeil R. Acceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study. PLOS ONE 2025, 20: e0319010. PMID: 40019916, PMCID: PMC11870339, DOI: 10.1371/journal.pone.0319010.Peer-Reviewed Original ResearchConceptsAdherence to antiretroviral therapyLong-acting antiretroviral therapyLA-ARTAntiretroviral therapySuboptimal adherence to antiretroviral therapyAdherence barriersProspective cohort studySuboptimal ART adherenceAdverse side effectsPill burdenTreatment optionsSubstance useCohort studyART adherenceTreatment advancesSide effectsTreatment changesPLHIVTreatment approachesTherapyCredible sources of informationPopulation-level benefitsDrugHIVSocial-structural inequities
2024
Determinants of undervaccination of routine childhood immunization in Argentina: A cross-sectional study
Melchinger H, Winters M, Christie S, Arias N, Lirman L, Abeyesekera S, Thomson A, Omer S. Determinants of undervaccination of routine childhood immunization in Argentina: A cross-sectional study. Vaccine 2024, 42: 126235. PMID: 39182313, DOI: 10.1016/j.vaccine.2024.126235.Peer-Reviewed Original ResearchConceptsRoutine childhood immunizationChildhood immunizationRoutine immunizationAdverse side effectsCross-sectional studyOfficial health organizationsRoutine immunization coverageSide effectsVaccination scheduleTarget parentsImmunization coverageParental concernsImmunityVaccineUnder-vaccinationVaccination adviceHealth OrganizationEvidence to dateOlder parentsInfectious diseasesPreferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey.
Bromberg D, Madden L, Fraenkel L, Muthulingam D, Rhoades D, Dvoriak S, Dumchev K, Pykalo I, Altice F. Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey. PLOS Global Public Health 2024, 4: e0002725. PMID: 38277422, PMCID: PMC10817130, DOI: 10.1371/journal.pgph.0002725.Peer-Reviewed Original ResearchOpioid agonist therapyWithdrawal symptomsAdverse side effectsAgonist therapySide effectsOpioid use disorderQuality-of-life improvementUse disorderCombined HIVHIV incidenceClinical decision-makingDosing frequencyRespondent-driven samplingOpioidOpioid epidemicAssess preferencesClinical concernPatient preferencesPatientsDelivery strategiesTherapyDisordersHIVPatient concernsWithdrawal
2021
The Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study
Post G, Lustgarten J. The Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study. Topics In Companion Animal Medicine 2021, 46: 100616. PMID: 34864255, DOI: 10.1016/j.tcam.2021.100616.Peer-Reviewed Original ResearchConceptsOligo-FucoidanComplete blood countLife metricsLife scoresDouble-blinded studyMinimal adverse side effectsCase-control studyPlacebo control groupAdverse side effectsSignificant differencesQuality of lifeDiagnosis of cancerSerum biochemical parametersSerum biochemistry profilePlacebo groupUndergoing ChemotherapyProspective studyPhysical examinationBlood countCancer CenterFucoidan groupBlinded cliniciansLife QuestionnaireVeterinary patientsSide effectsA Polyphenol-Rich Extract of Olive Mill Wastewater Enhances Cancer Chemotherapy Effects, While Mitigating Cardiac Toxicity
Albini A, Festa M, Ring N, Baci D, Rehman M, Finzi G, Sessa F, Zacchigna S, Bruno A, Noonan D. A Polyphenol-Rich Extract of Olive Mill Wastewater Enhances Cancer Chemotherapy Effects, While Mitigating Cardiac Toxicity. Frontiers In Pharmacology 2021, 12: 694762. PMID: 34434106, PMCID: PMC8381749, DOI: 10.3389/fphar.2021.694762.Peer-Reviewed Original ResearchHearts of miceSide effectsRat cardiomyocytesPotential cardioprotective activityEffect of chemotherapyProstate cancer xenograftsAdverse side effectsColon cancer cell growthCancer cell growthPolyphenol-rich extractAnti-oxidant activityAnti-cancer activityCardiovascular preventionCardioprotective effectsTumor weightCardiac toxicityCancer patientsCardiovascular toxicityCancer xenograftsCardioprotective roleProtective effectCancer chemotherapy effectsMouse pupsCardioprotective activityChemotherapy effectTrends in Medication Prescribing in Patients With PTSD From 2009 to 2018: A National Veterans Administration Study.
Holder N, Woods A, Neylan TC, Maguen S, Seal KH, Bernardy N, Wiechers I, Ryder A, Urbieta AM, Cohen BE. Trends in Medication Prescribing in Patients With PTSD From 2009 to 2018: A National Veterans Administration Study. The Journal Of Clinical Psychiatry 2021, 82 PMID: 34004087, DOI: 10.4088/jcp.20m13522.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntipsychotic AgentsDrug PrescriptionsHumansLongitudinal StudiesMaleMiddle AgedPractice Patterns, Physicians'Psychotropic DrugsRetrospective StudiesSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsStress Disorders, Post-TraumaticUnited StatesUnited States Department of Veterans AffairsVeteransConceptsPosttraumatic stress disorderPercentage of patientsVeterans Health AdministrationVHA careAdjunctive medicationsOutpatient prescription recordsSSRIs/SNRIsVeterans Administration studyClinical practice guidelinesICD-10 codesAdverse side effectsEvidence-based psychotherapiesPsychotic spectrum disordersAAP useMedication classesBenzodiazepine prescriptionsMedication prescribingPrescription recordsSymptom improvementNational cohortPractice guidelinesMedicationsSide effectsICD-9Patients
2019
Renal clearable nanochelators for iron overload therapy
Kang H, Han M, Xue J, Baek Y, Chang J, Hu S, Nam H, Jo M, El Fakhri G, Hutchens M, Choi H, Kim J. Renal clearable nanochelators for iron overload therapy. Nature Communications 2019, 10: 5134. PMID: 31723130, PMCID: PMC6853917, DOI: 10.1038/s41467-019-13143-z.Peer-Reviewed Original ResearchConceptsIron overloadIntravenous injectionDaily sc injectionsUrinary iron excretionSecondary iron overloadIron-overloaded miceAdverse side effectsIron chelatorsIron overload disordersGastrointestinal bleedingSC injectionIron excretionLiver fibrosisSide effectsKidney damageKidney failureIron overload therapyIron levelsToxic ironPharmacokinetic propertiesDeferoxamineNanochelatorKidneyExcretionInjectionPain symptomology, functional impact, and treatment of people with Neurofibromatosis type 1
Buono FD, Grau LE, Sprong ME, Morford KL, Johnson KJ, Gutmann DH. Pain symptomology, functional impact, and treatment of people with Neurofibromatosis type 1. Journal Of Pain Research 2019, 12: 2555-2561. PMID: 31692483, PMCID: PMC6710538, DOI: 10.2147/jpr.s209540.Peer-Reviewed Original ResearchNeurofibromatosis type 1Pain severityPain symptomsType 1Potential adverse side effectsPrescription pain medicationAdverse side effectsTreatment of peopleMedication dependenceOpioid medicationsPain medicationPain managementPain symptomatologyCurrent treatmentMalignant tumorsPain dataSurgical proceduresComplementary treatmentHigh incidenceAlternative treatmentSide effectsCareful monitoringMedicationsDaily functioningInitiative databaseTreating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes
Makarenko I, Pykalo I, Springer SA, Mazhnaya A, Marcus R, Filippovich S, Dvoriak S, Altice FL. Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. Journal Of Substance Use And Addiction Treatment 2019, 104: 34-41. PMID: 31370983, PMCID: PMC8215516, DOI: 10.1016/j.jsat.2019.05.008.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist treatmentXR-NTX injectionXR-NTX treatmentXR-NTXUrine drug testingOpioid useExtended-release naltrexoneMonths of treatmentThree-month outcomeHealth-related qualityAdverse side effectsSymptoms of depressionOpioid dependenceAgonist treatmentLife scoresTreatment optionsIndependent factorsSide effectsUse disordersPeriod of observationDrug useStimulant useTreatment motivationDrug testingAnalysis of Multiple Routes of Analgesic Administration in the Immediate Postoperative Period: a 10-Year Experience
Vadivelu N, Kai AM, Dai F, Dabu-Bondoc S. Analysis of Multiple Routes of Analgesic Administration in the Immediate Postoperative Period: a 10-Year Experience. Current Pain And Headache Reports 2019, 23: 22. PMID: 30854578, DOI: 10.1007/s11916-019-0754-4.Peer-Reviewed Original ResearchConceptsPain scoresAnalgesic administrationPostoperative painPost-anesthesia care unitYale-New Haven HospitalImmediate postoperative painPostoperative pain scoresPurpose of ReviewAnSignificant pain reliefImmediate postoperative periodConsecutive surgical casesTime of dischargeRoute of administrationCommon routeAdverse side effectsNew Haven HospitalIndividual analgesicsNeuraxial routeAnalgesia administrationNeuraxial analgesiaPain reliefPostoperative periodSynergistic analgesiaCare unitParenteral routeEndocrine‐related quality of life in a randomized trial of exercise on aromatase inhibitor–induced arthralgias in breast cancer survivors
Baglia ML, Lin I, Cartmel B, Sanft T, Ligibel J, Hershman DL, Harrigan M, Ferrucci LM, Li F, Irwin ML. Endocrine‐related quality of life in a randomized trial of exercise on aromatase inhibitor–induced arthralgias in breast cancer survivors. Cancer 2019, 125: 2262-2271. PMID: 30840336, PMCID: PMC6731173, DOI: 10.1002/cncr.32051.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsUsual care groupCancer survivorsAdverse side effectsCare groupOverall QOLSide effectsAromatase Inhibitor-Induced ArthralgiaCancer Therapy questionnaireExercise intervention groupTrial of exerciseShort Form SurveyPhysical exercise studiesBreast cancer treatmentOverall QOL measuresRepeated-measures analysisMild arthralgiaTreatment discontinuationExercise groupExercise interventionNonpharmacologic interventionsResistance exerciseExercise studiesAromatase inhibitorsIntervention group
2017
Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain Abnormalities
Ornaghi S, Hsieh LS, Bordey A, Vergani P, Paidas MJ, van den Pol AN. Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain Abnormalities. Journal Of Neuroscience 2017, 37: 6877-6893. PMID: 28630251, PMCID: PMC5518418, DOI: 10.1523/jneurosci.0970-17.2017.Peer-Reviewed Original ResearchConceptsAnti-CMV drugsBrain defectsNeurological outcomeCMV replicationMouse brainAvailable anti-CMV drugsHuman fetal brain cellsLong-term neurological outcomeTreatment of cytomegalovirusAdverse neurological outcomesUninfected control miceCommon infectious causeLong-term motorSecond trimester human fetusesUninfected control animalsFetal brain cellsHuman fetal astrocytesJuvenile male miceWeeks of lifeAdverse side effectsEfficacious therapeutic effectsDetectable adverse effectsNewborn mouse brainLevels of virusCMV infection
2016
Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone
Lawres LA, Garg A, Kumar V, Bruzual I, Forquer IP, Renard I, Virji AZ, Boulard P, Rodriguez EX, Allen AJ, Pou S, Wegmann KW, Winter RW, Nilsen A, Mao J, Preston DA, Belperron AA, Bockenstedt LK, Hinrichs DJ, Riscoe MK, Doggett JS, Mamoun C. Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone. Journal Of Experimental Medicine 2016, 213: 1307-1318. PMID: 27270894, PMCID: PMC4925016, DOI: 10.1084/jem.20151519.Peer-Reviewed Original ResearchConceptsExperimental babesiosisHuman babesiosisImmunodeficient miceRadical cureELQ-334Discontinuation of therapyFuture clinical evaluationEndochin-like quinolonesVivo efficacy studiesAdverse side effectsRecrudescent parasitesMost clinical casesCombination therapyMultisystem diseaseClinical evaluationComplete clearanceCurrent treatmentDrug combinationsDrug failureSide effectsExcellent growth inhibitory activityEfficacy studiesClinical casesGrowth inhibitory activityAtovaquoneEffects of Amiodarone and N-desethylamiodarone on Cardiac Voltage-Gated Sodium Channels
Ghovanloo MR, Abdelsayed M, Ruben PC. Effects of Amiodarone and N-desethylamiodarone on Cardiac Voltage-Gated Sodium Channels. Frontiers In Pharmacology 2016, 7: 39. PMID: 26973526, PMCID: PMC4771766, DOI: 10.3389/fphar.2016.00039.Peer-Reviewed Original ResearchEffects of amiodaronePro-arrhythmic effectsAntiarrhythmic drugsN-desethylamiodaroneLate sodium currentPotent antiarrhythmic drugDrug-mediated effectsAdverse side effectsAtrial fibrillationPharmacologic profileQT intervalAmiodaroneSide effectsCardiac voltageWindow currentSodium currentClass ISodium channelsHigh efficacyDrugsPeak conductanceNav1.5Similar profilesTorsadesTachycardia
2015
Lassa-Vesicular Stomatitis Chimeric Virus Safely Destroys Brain Tumors
Wollmann G, Drokhlyansky E, Davis JN, Cepko C, van den Pol AN. Lassa-Vesicular Stomatitis Chimeric Virus Safely Destroys Brain Tumors. Journal Of Virology 2015, 89: 6711-6724. PMID: 25878115, PMCID: PMC4468483, DOI: 10.1128/jvi.00709-15.Peer-Reviewed Original ResearchConceptsLymphocytic choriomeningitis virusBrain tumorsVesicular stomatitis virusChimeric virusesBrain cancerLassa virusEbola virusMarburg virusRabies virusAdverse neurologic consequencesExquisite tumor specificityHigh-grade tumorsPromising oncolytic virusLassa virus glycoprotein precursorAdverse side effectsTumor-bearing miceMetastatic cancer modelsStomatitis virusNovel chimeric virusHigh-grade glioblastomaEbola virus glycoproteinMultiple cancer typesNoninjected tumorNeurologic consequencesOncolytic potential
2012
A marriage made to last in drug design
Dietrich MO, Horvath TL. A marriage made to last in drug design. Nature Medicine 2012, 18: 1737-1738. PMID: 23223057, DOI: 10.1038/nm.3018.Peer-Reviewed Original Research
2009
HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin
Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, Friedman A, Jain D, Bia M, Formica R, Mehal W. HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin. Journal Of Clinical Gastroenterology 2009, 43: 477-481. PMID: 19142165, PMCID: PMC3715868, DOI: 10.1097/mcg.0b013e318180803a.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseHepatitis C virusCombination therapyRenal diseasePosttreatment rateSide effectsSerious adverse side effectsDose of ribavirinNon-ESRD patientsSafe therapeutic optionEarly virologic responseProspective observational studyMonths of treatmentStage renal diseaseCases of anemiaInitial response rateLength of treatmentInterferon α-2aAdverse side effectsPO weeklyVirologic responseESRD patientsHCV infectionESRD populationHCV responseChapter 98 The Use of 131Iodine in the Treatment of Graves’ Disease in Children
Rivkees S, Dinauer C. Chapter 98 The Use of 131Iodine in the Treatment of Graves’ Disease in Children. 2009, 942-955. DOI: 10.1016/b978-0-12-374135-6.00098-4.ChaptersGraves' diseaseRadioactive iodineThyroid cancerSide effectsLong-term adverse side effectsLong-term remission ratesRecurrent laryngeal nerve paresisPreferred definitive treatmentTreatment of GravesAcute side effectsBone marrow suppressionLaryngeal nerve paresisLong-term complicationsSerious adverse reactionsCurrent treatment optionsHigh cure ratesLarge thyroid glandForm of surgeryAdverse side effectsGenetic damageAntithyroid medicationDefinitive therapyNerve paresisPermanent hypoparathyroidismRemission rate
2007
Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services
Sylla L, Bruce RD, Kamarulzaman A, Altice FL. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. International Journal Of Drug Policy 2007, 18: 306-312. PMID: 17689379, PMCID: PMC2696234, DOI: 10.1016/j.drugpo.2007.03.001.Peer-Reviewed Original ResearchConceptsInjection drug useSubstance use treatmentDrug usersEffective substance use treatmentTraining Community Health WorkersActive injection drug useUse treatmentIntegrated care delivery systemSpecialist care providersAdverse drug eventsCommunity health workersComplex patient populationInjection drug usersAdverse side effectsDrug treatment servicesDrug-drug interactionsDetection of tuberculosisCare delivery systemHIV/AIDSAntiretroviral medicationsMedication adherencePatient populationDrug eventsHIV epidemicHealth workersAn Optimal Treatment for Pediatric Graves’ Disease Is Radioiodine
Rivkees SA, Dinauer C. An Optimal Treatment for Pediatric Graves’ Disease Is Radioiodine. The Journal Of Clinical Endocrinology & Metabolism 2007, 92: 797-800. PMID: 17341574, DOI: 10.1210/jc.2006-1239.Commentaries, Editorials and LettersConceptsGraves' diseaseAntithyroid medicationRadioactive iodineThyroid cancerSide effectsLong-term adverse side effectsPediatric Graves' diseaseAcute side effectsLong-term remissionTreatment of hyperthyroidismAdverse side effectsMajority of childrenCurative therapyThyroid irradiationPediatric populationSpontaneous remissionOptimal treatmentSufficient dosesDefinite riskTreatment approachesMedicationsEffective cureDiseaseRemissionChildren
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply